Cytogenetic abnormalities in essential thrombocythemia: Prevalence and prognostic significance

European Journal of Haematology

Volumn 83, Issue 1, 2009, Pages 17-21

  Gangat, Naseema ^a   Tefferi, Ayalew ^a   Thanarajasingam, Gita ^a   Patnaik, Mrinal ^a   Schwager, Susan ^a   Ketterling, Rhett ^a   Wolanskyj, Alexandra P ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cytogenetics; Essential thrombocythemia; Karyotype; Myeloid disorders

Indexed keywords

HEMOGLOBIN; JAK2 PROTEIN, HUMAN; JANUS KINASE 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANEMIA; ARTERY THROMBOSIS; ARTICLE; BLEEDING; CHROMOSOME 1; CHROMOSOME 10; CHROMOSOME 11; CHROMOSOME 13Q; CHROMOSOME 2; CHROMOSOME 20Q; CHROMOSOME 3P; CHROMOSOME 4; CHROMOSOME 5Q; CHROMOSOME 6; CHROMOSOME 7Q; CHROMOSOME 9; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; KARYOTYPE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MYELOFIBROSIS; PARTIAL TRISOMY 9; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SENESCENCE; SMOKING; SPLENOMEGALY; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTHEMIA; TRISOMY 8; VEIN THROMBOSIS; ADOLESCENT; AGED; CHILD; CHROMOSOME 8; COHORT ANALYSIS; GENETICS; KARYOTYPING; MIDDLE AGED; MUTATION; MYELOID METAPLASIA; PRESCHOOL CHILD; TRISOMY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 8; CHROMOSOMES, HUMAN, PAIR 9; COHORT STUDIES; FEMALE; HUMANS; JANUS KINASE 2; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; PRIMARY MYELOFIBROSIS; PROGNOSIS; THROMBOCYTHEMIA, ESSENTIAL; TRISOMY; YOUNG ADULT;

EID: 67649515749     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2009.01246.x     Document Type: Article

References (14)

1. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007 110 : 1092 7.
2. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008 22 : 14 22.
3. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006 81 : 159 66.
4. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004 117 : 755 61.
5. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005 434 : 1144 8.
6. Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005 131 : 208 13.
7. Antonioli E, Guglielmelli P, Pancrazzi A, et al. Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005 19 : 1847 9.
8. Panani AD. Cytogenetic findings in untreated patients with essential thrombocythemia. In Vivo 2006 20 : 381 4.
9. Swolin B, Safai-Kutti S, Anghem E, Kutti J. No increased frequency of trisomies 8 and 9 by fluorescence in situ hybridization in untreated patients with essential thrombocythemia. Cancer Genet Cytogenet 2001 126 : 56 9.
10. Herishanu Y, Lishner M, Bomstein Y, et al. Comparative genomic hybridization in polycythemia vera and essential thrombocytosis patients. Cancer Genet Cytogenet 2001 128 : 154 7.
11. Dewald GW, Broderick DJ, Tom WW, Hagstrom JE, Pierre RV. The efficacy of direct, 24-hour culture, and mitotic synchronization methods for cytogenetic analysis of bone marrow in neoplastic hematologic disorders. Cancer Genet Cytogenet 1985 18 : 1 10. (Pubitemid 15017267)
12. Levine RL, Belisle C, Wadleigh M, et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006 107 : 4139 41.
13. Sessarego M, Defferrari R, Dejana AM, et al. Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation. A 12-year study. Cancer Genet Cytogenet 1989 43 : 57 65. (Pubitemid 19281690)
14. Panani AD. Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: clinical implications. Cancer Lett 2007 255 : 12 25. (Pubitemid 47225135)